Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guoqiang Zhang has a total of 238 co-authors. Here are the top co-authors by number of shared publications:

  • Nan Gao

    China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China

    16 shared publications
  • Jie Chen

    Department of Emergency, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100029, China

    13 shared publications
  • A-Ling Tang

    Department of Emergency, China-Japan Friendship Hospital, Beijing 100029, China

    9 shared publications
  • Rui Lian

    Department of Emergency, China-Japan Friendship Hospital

    9 shared publications
  • Xiaoyu Liu

    Department of Emergency, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100029, China

    9 shared publications
  • Cheng Xiao

    Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, 100029, China

    8 shared publications

Latest Publications

  • SERPINE1 in ARDS: an emerging regulator of inflammation–coagulation–fibrinolysis crosstalk

    by Nan Gao, Song Yang, Wei-Jian Zhang, Hao-Tian Lu, Zheng-Nan Zhang, Yi-Xin Qian, Guo-Qiang Zhang

    Objective and design This narrative review synthesizes current evidence on the role of SERPINE1/PAI-1 in acute respiratory distress syndrome (ARDS), with particular emphasis on inflammation–coagulation–fibrinolysis crosstalk. Material or subjects Published experimental, translational, genetic, and clinical studies addressing SERPINE1/PAI-1 in ARDS and related critical illnesses were summarized. Treatment Not applicable. Methods We summarized evidence on the pathobiological functions, cellular sources, biomarker potential, genetic associations, and therapeutic implications of SERPINE1/PAI-1. Results SERPINE1 limits tissue-type and urokinase-type plasminogen activator activity, thereby promoting hypofibrinolysis and persistent fibrin deposition in the injured lung. Experimental and clinical evidence further links elevated PAI-1 to inflammatory amplification, endothelial injury, pulmonary microvascular thrombosis, greater disease severity, and adverse outcomes, although the strength of evidence and the degree of causal support vary across these processes. High-expression SERPINE1 variants may also influence clinical outcomes in selected critical illness settings. Pharmacological PAI-1 inhibition is biologically plausible, but its translation to ARDS remains limited by disease heterogeneity, uncertainty regarding treatment timing, and the risk of bleeding. Conclusions SERPINE1 is a potentially important integrative regulator and biomarker of dysregulated inflammation, coagulation, and fibrinolysis in ARDS. Future studies should clarify its causal, cell-specific, and phenotype-dependent roles to facilitate the development of targeted therapeutic strategies.


  • Open Access

    SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD+ homeostasis and suppressing Sirt3 activity

    by Nan Gao, Wei-Jian Zhang, Yi-Xin Qian, Song Yang, Zheng-Nan Zhang, Hao-Tian Lu, Guo-Qiang Zhang


  • Open Access

    Identification of FTO as a key m6A demethylase linking immune dysregulation to sepsis pathogenesis

    by Yi Jiao, Rui Lian, Weijian Zhang, Nan Gao, Qishun Geng, Tiantian Deng, Zhaoran Wang, Tingting Deng, Cheng Xiao, Guoqiang Zhang

    Background: Sepsis is a life-threatening disorder characterized by multiple organ dysfunction caused by dysregulated host responses to infection. The present study aimed to identify potential diagnostic biomarkers for sepsis and elucidate their molecular mechanisms through comprehensive bioinformatics and experimental analyses. Methods: Five publicly available transcriptomic datasets (GSE13904, GSE26440, GSE28750, GSE95233, and GSE57065) containing sepsis and healthy control samples were utilized in the study. After quality control and normalization, the samples were divided into training and validation cohorts. Fourteen machine learning algorithms were applied to the training cohort to identify robust diagnostic biomarkers, and their predictive performance was subsequently verified in the validation cohorts. Single-cell RNA sequencing (scRNA-seq) data were further analyzed to determine the cellular distribution of the identified regulators among immune cell subsets. Results: In total, the least absolute shrinkage and selection operator (LASSO) model exhibited the best performance in the validation set, demonstrating high reliability. Through consensus feature selection across multiple models, the m 6 A methylation regulator fat mass and obesity-associated protein (FTO) was identified as a key biomarker. scRNA-seq analysis revealed that FTO was primarily expressed in neutrophils and macrophages. Its expression levels were markedly altered in peripheral blood mononuclear cells (PBMCs) and neutrophils from sepsis patients compared with healthy controls, which was consistent with the findings in in vitro macrophage and neutrophil models. Functional experiments demonstrated that FTO promotes macrophage polarization toward the pro-inflammatory M1 phenotype and enhances neutrophil inflammatory and chemotactic responses, highlighting its critical role in orchestrating inflammatory regulation during sepsis. Conclusion: FTO, identified through consensus machine learning approaches, could serve as a potential diagnostic biomarker and m 6 A methylation regulator for sepsis. The discovery of FTO and its downstream targets provides new insights into sepsis pathogenesis and may offer a foundation for developing novel therapeutic strategies.


  • Open Access

    m6A methylation in ferroptosis regulation: mechanisms, targets, and therapeutic interventions

    by Chaoying Wen, Yi Jiao, Zhaoran Wang, Tong Shi, Yan Wang, Jiahe Xu, Tiantian Deng, Guoqiang Zhang, Cheng Xiao


  • Open Access

    Chinese emergency expert consensus on the diagnosis and treatment of sepsis-associated encephalopathy in the elderly

    by Wei Gu, Jie Zhong, Yongli Han, Yuxiang Liu, Chuanzhu Lv, Guoqiang Zhang, Miaorong Xie, Yuefeng Ma, Wei Guo

    Sepsis-associated encephalopathy (SAE) is a diffuse dysfunction of the nervous system resulting from sepsis originating outside the central nervous system. The elderly (≥65 years of age) are a particularly vulnerable population, and the emergency department is typically the first point of contact following onset of SAE. Clinical symptoms in elderly patients with SAE are often atypical, compounded by a high burden of underlying diseases and complications, which frequently leads to underdiagnosis or misdiagnosis. These patients are at increased risk of long-term or permanent central nervous system impairment, making rapid and accurate diagnosis and treatment especially critical. Currently, there are no standardized diagnostic or treatment guidelines tailored specifically to geriatric SAE. This expert consensus, grounded in evidence-based medicine and clinical experience, offers recommendations on the risk factors, clinical characteristics, diagnosis, and treatment of geriatric SAE. The goal is to standardize care, improve diagnostic accuracy, reduce mortality, and enhance patient outcomes.

  • Identification of key genes and development of an identifying machine learning model for sepsis

    by Zhonghao Li, Shengsong Chen, Nan Gao, Jie Chen, Ying Qin, Guoqiang Zhang

    Objective and design This study aims to identify key genes of sepsis and construct a model for sepsis identification through integrated multi-organ single-cell RNA sequencing (scRNA-seq) and machine learning. Material or subjects Datasets downloaded from the Gene Expression Omnibus (GSE207363, GSE207651, GSE185263, GSE69063 and GSE134347) were used. Methods ScRNA-seq data extracted from heart (GSE207363) and lung tissues (GSE207651) of septic mice were processed and analyzed using the Seurat package in R. Key genes were identified as present in both heart and lung tissues, resulting from the overlap of three analyses along with differential expression analyses. We then used support vector machine recursive feature elimination to construct a model for sepsis identification based on these key genes. The GSE185263 dataset was used for training, while GSE69063 and GSE134347 were used for testing. The accuracy of the model in identifying of sepsis was validated by analyzing the area under the receiver operating characteristic curve (AUROC) using the test datasets. Results Thirteen genes were initially identified as key genes, and after translation to their human homologs, ten genes remained. The optimal SVM-RFE model incorporated eight of these genes (CAMP, CD74, HLA-DQA1, HLA-DQB1, HLA-DMA, HLA-DRB5, and LYZ). In the two test datasets, the AUROC value for the accuracy of the model in identifying of sepsis was 0.904 and 0.924, respectively. Conclusions We have identified several key genes and developed a machine learning model for sepsis identification. Further studies are needed to validate our findings.


  • Open Access

    Guideline for antibacterial therapy of adult community-acquired pneumonia in the emergency department under the physician-pharmacist collaborative management model

    by Gu Wei, Shuo Wang, Ling Wang, Yang Liu, Chuanzhu Lv, Guoqiang Zhang, Yuefeng Ma, Wei Guo

    Community-acquired pneumonia (CAP) in adults (≥18 years old) is the most common infectious disease encountered in emergency departments. Its clinical complexity and the need for prompt treatment decisions pose significant challenges for patient management. The physician-pharmacist collaborative management (PPCM) model, which optimizes drug therapy regimens through collaboration between physicians and clinical pharmacists, has demonstrated strong clinical value in practice. However, the lack of standardized national guidelines for the application of the PPCM model in emergency departments in China has hampered its widespread adoption. This guideline is developed based on evidence-based medicine and clinical practice experience, with a focus on the application of the PPCM model in the management of CAP in emergency settings. It outlines the significance of the PPCM model, its applicable scenarios, the respective roles of emergency physicians and clinical pharmacists, and its practical implementation in the antimicrobial treatment of CAP patients. In addition, the guideline proposes standardized implementation processes and clinical pathways. By promoting the PPCM model, the expert panel aims to standardize the use of antimicrobial agents in the emergency treatment of CAP, reduce the risk of antimicrobial resistance, and improve patient outcomes.


  • Open Access

    Guideline for antibacterial therapy of adult community-acquired pneumonia in the emergency department under the physicianpharmacist collaborative management model

    by Wei Gu, Shuo Wang, Ling Wang, Yang Liu, Chuanzhu Lv, Guoqiang Zhang, Yuefeng Ma, Wei Guo

    Community-acquired pneumonia (CAP) in adults (⩾18 years old) is the most common infectious disease encountered in emergency departments. Its clinical complexity and the need for prompt treatment decisions pose significant challenges for patient management. The physician-pharmacist collaborative management (PPCM) model, which optimizes drug therapy regimens through collaboration between physicians and clinical pharmacists, has demonstrated strong clinical value in practice. However, the lack of standardized national guidelines for the application of the PPCM model in emergency departments in China has hampered its widespread adoption. This guideline is developed based on evidence-based medicine and clinical practice experience, with a focus on the application of the PPCM model in the management of CAP in emergency settings. It outlines the significance of the PPCM model, its applicable scenarios, the respective roles of emergency physicians and clinical pharmacists, and its practical implementation in the antimicrobial treatment of CAP patients. In addition, the guideline proposes standardized implementation processes and clinical pathways. By promoting the PPCM model, the expert panel aims to standardize the use of antimicrobial agents in the emergency treatment of CAP, reduce the risk of antimicrobial resistance, and improve patient outcomes.